Want to see HK:9989 full AI Analyst Report?
9989 Stock Chart & Stats
HK$5.19
HK$0.02(0.54%)
At close: 4:00 PM EST
HK$5.19
HK$0.02(0.54%)
Day’s Range― - ―
52-Week RangeHK$3.74 - HK$6.82
Previous CloseN/A
Volume172.00K
Average Volume (3M)1.16M
Market Cap
HK$14.99B
Enterprise ValueHK$6.85K
Total Cash (Recent Filing)HK$3.50B
Total Debt (Recent Filing)HK$2.79B
Price to Earnings (P/E)37.3
Beta1.00
Next Earnings
Aug 29, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend Yield3.86%
Share Statistics
EPS (TTM)0.26
Shares Outstanding220,094,500
10 Day Avg. Volume947,650
30 Day Avg. Volume1,161,300
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)0.57
Price to Sales (P/S)1.25
P/FCF Ratio4.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.56
Revenue Forecast (FY)HK$6.58B
Bulls Say, Bears Say
Bulls Say
Cash Generation QualityFree cash flow equaling ~93% of net income indicates high earnings quality and internal funding capacity. Over months this supports capex, R&D, dividends and lowers refinancing need, improving financial flexibility even if cash momentum can vary across cycles.
Moderate Leverage / Resilient Balance SheetA debt-to-equity near 0.18 and a sizable equity base provide resilience versus downturns and reduce refinancing risk. This durable capital structure allows prioritized reinvestment or payouts and supports operations through regulatory or raw-material disruptions.
Vertical Integration In Heparin Value ChainControl of upstream API production through downstream finished products creates a structural competitive edge: better raw-material sourcing, processing yields, quality control and customer ties. This integration supports margin stability and supply security over months to years.
Bears Say
Stagnant Revenue & Profit CompressionFlat-to-declining revenue and compressed operating profitability signal limited pricing power or market growth. Structurally, this constrains reinvestment capacity and long-term margin recovery unless product mix, pricing or market share trends materially improve.
Volatile Multi-year Cash Flow HistoryPast negative operating and free cash flow years indicate cash generation can be cyclical and unreliable. This volatility makes capital planning, consistent dividends or sustained R&D investment riskier absent stronger, sustained cash conversion going forward.
Low Returns On EquityROE near 3% shows the business struggles to convert equity into high returns. Over the medium term this limits shareholder value creation, constrains ability to self-fund growth at attractive returns, and raises scrutiny on capital allocation.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H News
9989 FAQ
What was Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price range in the past 12 months?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H lowest stock price was HK$3.74 and its highest was HK$6.82 in the past 12 months.
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap is HK$14.99B.
When is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s upcoming earnings report date?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s upcoming earnings report date is Aug 29, 2026 which is in 20 days.
How were Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s earnings last quarter?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H released its earnings results on Apr 29, 2026. The company reported HK$0.147 earnings per share for the quarter, beating the consensus estimate of HK$0.126 by HK$0.021.
Is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H overvalued?
According to Wall Street analysts Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price is currently Overvalued.
Does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pay dividends?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pays a Annually dividend of HK$0.166 which represents an annual dividend yield of 3.86%. See more information on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H dividends here
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate is 0.09.
How many shares outstanding does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H have?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 220,094,500 shares outstanding.
What happened to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price movement after its last earnings report?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H reported an EPS of HK$0.147 in its last earnings report, beating expectations of HK$0.126. Following the earnings report the stock price went down -0.216%.
Which hedge fund is a major shareholder of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9989
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.12%
12-Months-Change
Fundamentals
Return on Equity
3.86%
Trailing 12-Months
Asset Growth
2.57%
Trailing 12-Months
Company Description
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) Earnings & Revenues
Technical Analysis
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Sihuan Pharmaceutical Holdings Group
―
China Resources Pharmaceutical Group Ltd.
―